Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878642 | 1.00 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL2067094 | 1.00 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL644767 | 1.00 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL150159 | 1.00 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL239938 | 1.00 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| Ammonia Solution, Strong SCHEMBL4410348 | 0.97 | DPP4 (0.93) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL9670481 | 0.97 | DPP4 (0.93) | DPP4F2HTR2ATAAR1ADRA2A | |
| Lithium SCHEMBL31260781 | 0.97 | DPP4 (0.93) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL10350027 | 0.97 | DPP4 (0.93) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL6743969 | 0.97 | DPP4 (0.93) | DPP4F2HTR2ATAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245089-A1 | PROCESSES FOR PREPARING TETRALIN COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-12441700-B2 | Hydrogenation of imines with RU complexes | FIRMENICHI SA (CH) | 2025-10-14 | — | — | US | claimed |
| CN-120040340-A | Method and device for continuously catalyzing and synthesizing tetramethyl piperidone | 潍坊元利新材料有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-115785155-B | Novel diindole ligand compound and synthesis method and application thereof | 凯特立斯（深圳）科技有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025104679-A1 | PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-22 | — | — | WO | claimed |
| WO-2025074394-A1 | A PROCESS FOR THE PREPARATION OF BELZUTIFAN AND ITS NOVEL INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2025-04-10 | — | — | WO | claimed |
| CN-119775208-A | Chiral bisimidazoline ligand containing cyclohexane skeleton structure and preparation method thereof | 北京化工大学 | 2025-04-08 | — | — | CN | claimed |
| EP-3694864-B1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA INC (US) | 2025-03-05 | — | — | EP | claimed |
| CN-114375290-B | Novel synthetic options for preparing compounds | 百时美施贵宝公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118231127-A | Schiff base nano zero-valent iron composite magnetic material and preparation method and application thereof | 长安大学 | 2024-06-21 | — | — | CN | claimed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | claimed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | claimed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | claimed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | claimed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | claimed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | claimed |
| US-6747152-B2 | COMPRISES MOLYBDENUM/TUNGSTEN/CHROMIUM COMPLEXES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2004-06-08 | — | — | US | claimed |
| US-20030191340-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-09 | — | — | US | claimed |
| EP-1049537-B1 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALLYLIC ALKYLATION | UNIV LELAND STANFORD JUNIOR (US) | 2003-08-06 | — | — | EP | claimed |
| US-20020198383-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441700-B2 | Hydrogenation of imines with RU complexes | HRH3, HNMT, HRH4 | DPP4 4188/4885F2 843/4885HTR2A 892/4885 |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | DPP4 216/4885F2 3296/4885HTR2A 943/4885 |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | DPP4 261/4885F2 3383/4885HTR2A 999/4885 |
| US-20020198383-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | MPG, UNG, APOBEC3C | DPP4 2820/4885F2 1620/4885HTR2A 4148/4885 |
| US-20030191340-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | MPG, UNG, APOBEC3C | DPP4 2820/4885F2 1620/4885HTR2A 4148/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | DPP4 261/4885F2 3383/4885HTR2A 999/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | DPP4 814/4885F2 1561/4885HTR2A 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.